Beyond transrectal ultrasound-guided prostate biopsies

available techniques and approaches

Christopher A Warlick, Jurgen Futterer, Mahir Maruf, Arvin K. George, Ardeshir R. Rastinehad, Peter A. Pinto, Ahmed El Shater Bosaily, Arnauld Villers, Caroline M. Moore, Neil Mendhiratta, Samir S. Taneja, Osamu Ukimura, Badrinath R Konety

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: Recent advances have led to the use of magnetic resonance imaging (MRI) alone or with fusion to transrectal ultrasound (TRUS) images for guiding biopsy of the prostate. Our group sought to develop consensus recommendations regarding MRI-guided prostate biopsy based on currently available literature and expert opinion. Methods: The published literature on the subject of MRI-guided prostate biopsy was reviewed using standard search terms and synthesized and analyzed by four different subgroups from among the authors. The literature was grouped into four categories—MRI-guided biopsy platforms, robotic MRI–TRUS fusion biopsy, template mapping biopsy and transrectal MRI–TRUS fusion biopsy. Consensus recommendations were developed using the Oxford Center for Evidence Based Medicine criteria. Results: There is limited high level evidence available on the subject of MRI-guided prostate biopsy. MRI guidance with or without TRUS fusion can lead to fewer unnecessary biopsies, help identify high-risk (Gleason ≥ 3 + 4) cancers that might have been missed on standard TRUS biopsy and identify cancers in the anterior prostate. There is no apparent significant difference between MRI biopsy platforms. Template mapping biopsy is perhaps the most accurate method of assessing volume and grade of tumor but is accompanied by higher incidence of side effects compared to TRUS biopsy. Conclusions: Magnetic resonance imaging-guided biopsies are feasible and better than traditional ultrasound-guided biopsies for detecting high-risk prostate cancer and anterior lesions. Judicious use of MRI-guided biopsy could enhance diagnosis of clinically significant prostate cancer while limiting diagnosis of insignificant cancer.

Original languageEnglish (US)
Pages (from-to)419-427
Number of pages9
JournalWorld Journal of Urology
Volume37
Issue number3
DOIs
StatePublished - Mar 12 2019

Fingerprint

Prostate
Image-Guided Biopsy
Biopsy
Magnetic Resonance Imaging
Prostatic Neoplasms
Neoplasms
Evidence-Based Medicine
Expert Testimony
Robotics
Tumor Burden
Incidence

Keywords

  • MRI biopsy
  • MRI fusion
  • Prostate cancer
  • Template biopsy

PubMed: MeSH publication types

  • Journal Article
  • Review

Cite this

Beyond transrectal ultrasound-guided prostate biopsies : available techniques and approaches. / Warlick, Christopher A; Futterer, Jurgen; Maruf, Mahir; George, Arvin K.; Rastinehad, Ardeshir R.; Pinto, Peter A.; Bosaily, Ahmed El Shater; Villers, Arnauld; Moore, Caroline M.; Mendhiratta, Neil; Taneja, Samir S.; Ukimura, Osamu; Konety, Badrinath R.

In: World Journal of Urology, Vol. 37, No. 3, 12.03.2019, p. 419-427.

Research output: Contribution to journalArticle

Warlick, CA, Futterer, J, Maruf, M, George, AK, Rastinehad, AR, Pinto, PA, Bosaily, AES, Villers, A, Moore, CM, Mendhiratta, N, Taneja, SS, Ukimura, O & Konety, BR 2019, 'Beyond transrectal ultrasound-guided prostate biopsies: available techniques and approaches', World Journal of Urology, vol. 37, no. 3, pp. 419-427. https://doi.org/10.1007/s00345-018-2374-8
Warlick, Christopher A ; Futterer, Jurgen ; Maruf, Mahir ; George, Arvin K. ; Rastinehad, Ardeshir R. ; Pinto, Peter A. ; Bosaily, Ahmed El Shater ; Villers, Arnauld ; Moore, Caroline M. ; Mendhiratta, Neil ; Taneja, Samir S. ; Ukimura, Osamu ; Konety, Badrinath R. / Beyond transrectal ultrasound-guided prostate biopsies : available techniques and approaches. In: World Journal of Urology. 2019 ; Vol. 37, No. 3. pp. 419-427.
@article{6ed114f945b749a4ac18110241746ba6,
title = "Beyond transrectal ultrasound-guided prostate biopsies: available techniques and approaches",
abstract = "Objectives: Recent advances have led to the use of magnetic resonance imaging (MRI) alone or with fusion to transrectal ultrasound (TRUS) images for guiding biopsy of the prostate. Our group sought to develop consensus recommendations regarding MRI-guided prostate biopsy based on currently available literature and expert opinion. Methods: The published literature on the subject of MRI-guided prostate biopsy was reviewed using standard search terms and synthesized and analyzed by four different subgroups from among the authors. The literature was grouped into four categories—MRI-guided biopsy platforms, robotic MRI–TRUS fusion biopsy, template mapping biopsy and transrectal MRI–TRUS fusion biopsy. Consensus recommendations were developed using the Oxford Center for Evidence Based Medicine criteria. Results: There is limited high level evidence available on the subject of MRI-guided prostate biopsy. MRI guidance with or without TRUS fusion can lead to fewer unnecessary biopsies, help identify high-risk (Gleason ≥ 3 + 4) cancers that might have been missed on standard TRUS biopsy and identify cancers in the anterior prostate. There is no apparent significant difference between MRI biopsy platforms. Template mapping biopsy is perhaps the most accurate method of assessing volume and grade of tumor but is accompanied by higher incidence of side effects compared to TRUS biopsy. Conclusions: Magnetic resonance imaging-guided biopsies are feasible and better than traditional ultrasound-guided biopsies for detecting high-risk prostate cancer and anterior lesions. Judicious use of MRI-guided biopsy could enhance diagnosis of clinically significant prostate cancer while limiting diagnosis of insignificant cancer.",
keywords = "MRI biopsy, MRI fusion, Prostate cancer, Template biopsy",
author = "Warlick, {Christopher A} and Jurgen Futterer and Mahir Maruf and George, {Arvin K.} and Rastinehad, {Ardeshir R.} and Pinto, {Peter A.} and Bosaily, {Ahmed El Shater} and Arnauld Villers and Moore, {Caroline M.} and Neil Mendhiratta and Taneja, {Samir S.} and Osamu Ukimura and Konety, {Badrinath R}",
year = "2019",
month = "3",
day = "12",
doi = "10.1007/s00345-018-2374-8",
language = "English (US)",
volume = "37",
pages = "419--427",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Beyond transrectal ultrasound-guided prostate biopsies

T2 - available techniques and approaches

AU - Warlick, Christopher A

AU - Futterer, Jurgen

AU - Maruf, Mahir

AU - George, Arvin K.

AU - Rastinehad, Ardeshir R.

AU - Pinto, Peter A.

AU - Bosaily, Ahmed El Shater

AU - Villers, Arnauld

AU - Moore, Caroline M.

AU - Mendhiratta, Neil

AU - Taneja, Samir S.

AU - Ukimura, Osamu

AU - Konety, Badrinath R

PY - 2019/3/12

Y1 - 2019/3/12

N2 - Objectives: Recent advances have led to the use of magnetic resonance imaging (MRI) alone or with fusion to transrectal ultrasound (TRUS) images for guiding biopsy of the prostate. Our group sought to develop consensus recommendations regarding MRI-guided prostate biopsy based on currently available literature and expert opinion. Methods: The published literature on the subject of MRI-guided prostate biopsy was reviewed using standard search terms and synthesized and analyzed by four different subgroups from among the authors. The literature was grouped into four categories—MRI-guided biopsy platforms, robotic MRI–TRUS fusion biopsy, template mapping biopsy and transrectal MRI–TRUS fusion biopsy. Consensus recommendations were developed using the Oxford Center for Evidence Based Medicine criteria. Results: There is limited high level evidence available on the subject of MRI-guided prostate biopsy. MRI guidance with or without TRUS fusion can lead to fewer unnecessary biopsies, help identify high-risk (Gleason ≥ 3 + 4) cancers that might have been missed on standard TRUS biopsy and identify cancers in the anterior prostate. There is no apparent significant difference between MRI biopsy platforms. Template mapping biopsy is perhaps the most accurate method of assessing volume and grade of tumor but is accompanied by higher incidence of side effects compared to TRUS biopsy. Conclusions: Magnetic resonance imaging-guided biopsies are feasible and better than traditional ultrasound-guided biopsies for detecting high-risk prostate cancer and anterior lesions. Judicious use of MRI-guided biopsy could enhance diagnosis of clinically significant prostate cancer while limiting diagnosis of insignificant cancer.

AB - Objectives: Recent advances have led to the use of magnetic resonance imaging (MRI) alone or with fusion to transrectal ultrasound (TRUS) images for guiding biopsy of the prostate. Our group sought to develop consensus recommendations regarding MRI-guided prostate biopsy based on currently available literature and expert opinion. Methods: The published literature on the subject of MRI-guided prostate biopsy was reviewed using standard search terms and synthesized and analyzed by four different subgroups from among the authors. The literature was grouped into four categories—MRI-guided biopsy platforms, robotic MRI–TRUS fusion biopsy, template mapping biopsy and transrectal MRI–TRUS fusion biopsy. Consensus recommendations were developed using the Oxford Center for Evidence Based Medicine criteria. Results: There is limited high level evidence available on the subject of MRI-guided prostate biopsy. MRI guidance with or without TRUS fusion can lead to fewer unnecessary biopsies, help identify high-risk (Gleason ≥ 3 + 4) cancers that might have been missed on standard TRUS biopsy and identify cancers in the anterior prostate. There is no apparent significant difference between MRI biopsy platforms. Template mapping biopsy is perhaps the most accurate method of assessing volume and grade of tumor but is accompanied by higher incidence of side effects compared to TRUS biopsy. Conclusions: Magnetic resonance imaging-guided biopsies are feasible and better than traditional ultrasound-guided biopsies for detecting high-risk prostate cancer and anterior lesions. Judicious use of MRI-guided biopsy could enhance diagnosis of clinically significant prostate cancer while limiting diagnosis of insignificant cancer.

KW - MRI biopsy

KW - MRI fusion

KW - Prostate cancer

KW - Template biopsy

UR - http://www.scopus.com/inward/record.url?scp=85049037657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049037657&partnerID=8YFLogxK

U2 - 10.1007/s00345-018-2374-8

DO - 10.1007/s00345-018-2374-8

M3 - Article

VL - 37

SP - 419

EP - 427

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 3

ER -